Israeli Multi Ethnic Centenarian Project

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

124 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-31

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will systematically assess epigenome methylation changes in participants of the Israel multi-ethnic centenarian study cohort, which includes citizens of Israel aged 95 years and older, compared to their offspring and younger controls.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Macroscopic and Molecular Changes in Knee Muscular - Tendon Unit in Response to Acute Resistant Load

NCT03332693

Physical Exertion

UNKNOWN NA

Surviving a Decade or More After Coronary Revascularization in a Middle Eastern Population

NCT03491722

Risk Factors AND Repeat Revascularization

COMPLETED

Adverse Myocardial and Vascular Side Effects of Immune Checkpoint Inhibitors

NCT04586894

Cancer Immune Defect Cardiovascular Abnormalities

COMPLETED

A Comparison of p53-induced Genes Activation in Patients With and Without Acute Myocardial Infarction

NCT01191879

Acute Myocardial Infarction

COMPLETED

Study to Evaluate the Performance of CardiacSense PPG Sensor

NCT04353453

Atrial Fibrillation

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The number of men and women reaching advanced age is rapidly increasing in developed countries and life expectancy has already doubled since the beginning of the last century. In parallel, the proportion of those who have survived to advanced old age without major health complications has become increasingly common. This phenomenon has led to concerted research efforts to understand the correlates and mechanisms of extended human longevity and healthy aging. For decades the public health perspective has emphasized environmental and life style factors as having beneficial effects on health and disease prevention in the general population. Important biological insights have been reached by examining the genetic basis of longevity and healthy aging, especially among individuals who demonstrate a favorable healthy aging phenotype. Epigenetics, defined as heritable changes in gene function or phenotypes, in the absence of DNA sequence changes, has revolutionized the concept of how genetics affect disease risk. Epigenetics have been shown to be associated with cancer risk and autoimmunity disorders. Moreover, epigenetic changes at specific sites appear to increase with age, hence they may serve as indices for chronological age. This background has led us to our central hypotheses that: i) epigenetic changes associated with healthy aging could serve as markers for a healthy life span, and ii) the epigenetic changes may represent one of the central mechanisms by which aging predisposes to many age-related diseases, and therefore affects healthy aging. We propose to test these hypotheses within the Israel multi-ethnic centenarian study cohort (which includes all citizens of Israel\>95 years old; an estimated 1 in 5000 of the population). We will systematically assess genomic methylation changes in three major sub-groups which signifies three major points in human lifespan: Age 60±5 years (leading age of onset of age associated diseases and also considered to represent the beginning of old age, age 80±5 years (average life expectancy in the western world), and age 100±5 years (exceptional longevity). Our centenarians includes 3 subgroups: SURVIVORS: those who survive and become centenarians in spite of early onset of cognitive impairment, functional disability or major age associated diseases, such as diabetes, vascular disease or cancer, at the beginning of old age, i.e., age of 60±5 years (thus long life span but short healthy lifespan). DELAYERS: those who develop age related diseases or cognitive/physical disability much later than the control population i.e., at the age of 80±5 years instead of 60 years (therefore have a longer healthy life span). DODGERS: those who fail to develop age-related illnesses or cognitive/physical disability throughout their life span. We will compare these groups to healthy controls with no family history of longevity in two reference groups, namely 60±5 years and 80±5 years, comparing them to the survivors and delayers groups, respectively. We predict that subjects will exhibit differences in methylation at sites distinct from each other, in contrast to healthy subjects.

Accordingly our proposed goals are:

1. To characterize the Israel multi-ethnic centenarian study cohort (I-MECS).
2. To screen, catalog and annotate epigenome methylation variants in five different groups (a. Survivors, b. Delayers, c. Dodgers, d. 60±5YO healthy control, and e. 80±5YO healthy controls).
3. To validate differential methylated loci by ranking and prioritizing using Sequenom's MassARRAY.
4. Exploratory goal (depend on time and funding availability) - To establish expression patterns using a qRT-PCR (Polymerase Chain Reaction) Roche light-cycler of the candidate epigenetic loci identified in Aims 1, 2 and 3 as well as specific genes (such as deoxyribonucleic acid methyltransferase and tumor suppressor genes) in blood cells of the initially screened population.

To test our hypotheses, we propose to employ a novel high-throughput genome-wide methylation assay, namely HELPtag. Additionally, we will utilize a combination of epigenome-wide association studies (EWAS) to identify the most distinctive epigenetic loci that show greatest differential methylation. We will then perform multi-locus validation for methylation status using MassARRAY.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

LONGEVITY 1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Older Cohort

Demographic, health and functional data will be collected from subjects 95 years and older by means of a structured interview. Blood will be collected for laboratory and genetic testing.

No interventions assigned to this group

Younger Controls

Demographic, health and functional data will be collected from the children of the older subjects and other aged-matched controls by means of a structured interview. Blood will be collected for laboratory and genetic testing.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 95 years and older.
* Provide verbal consent for participation in the study.
* Cognitively able to provide consent and answer a structured questionnaire.